About: The REal Life EVidence AssessmeNt Tool (RELEVANT): development of a novel quality assurance asset to rate observational comparative effectiveness research studies

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The REal Life EVidence AssessmeNt Tool (RELEVANT): development of a novel quality assurance asset to rate observational comparative effectiveness research studies Goto Sponge Distinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 27 March 2019

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) im März 2019 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en marzu de 2019 (ast) наукова стаття, опублікована у 2019 (uk) scientific article published on 27 March 2019 (en)
publication date	wds:Q64111023-FC9C2CA8-E3B0-4FF5-86F8-5321479CEB3B
publication date	2019-03-27 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q64111023-4DD5DED3-5C67-4D78-BC67-17584660272F
language of work or name	English
exact match	wds:Q64111023-30A555DB-07B6-4C0F-A4B0-D79874D6EC71
exact match	https://scigraph.springernature.com/pub.10.1186/s13601-019-0256-9
cites work	wds:Q64111023-14C55DF5-0737-40CD-888B-3A6FE17A3E7E wds:Q64111023-1DAB48DB-37A7-40F7-BA5E-0455428BA686 wds:Q64111023-483398DA-3A52-4D11-B9CA-595144E51F0C wds:Q64111023-4A3719EB-4467-4EF9-A91A-65C157401789 wds:Q64111023-59328EEA-A08F-489B-ABB6-65433A080F1A wds:Q64111023-5A06A49D-6E5A-4470-9CC1-2EF189481B1B wds:Q64111023-5A3B42D1-D071-4DAB-AE72-6D99E011E0FE wds:Q64111023-638E4804-1230-43CE-B244-03ACBCE47C65 wds:Q64111023-65A4AACC-8009-4209-871F-248105336E60 wds:Q64111023-693BFD57-09E6-424E-B7F7-6750A9C35954 wds:Q64111023-7C8564E3-88B6-4073-95D8-DCE1C7032CEA wds:Q64111023-7F13DC09-E8AE-4FA2-8C46-198CE41FC572 wds:Q64111023-8CDADF23-D8E9-44ED-882C-CCE9E50626DB wds:Q64111023-979E3B12-F960-4D12-AAE5-5F4AF778D2D3 wds:Q64111023-9C0E38BA-CBBD-4D5A-A73F-5CAF532F6A61 wds:Q64111023-AEE1C742-D0C9-44E3-965D-229684113C6B wds:Q64111023-B3916E99-3EAE-4E0B-91A6-62B8DAB308A5 wds:Q64111023-C0751543-8B5B-4D3A-885D-5CA619D83C0D wds:Q64111023-C20069CE-6010-40E4-B24F-6825BA676555 wds:Q64111023-D97A4A31-F05E-41AF-9455-4C3E01C16E3D wds:Q64111023-E81A7525-244F-45E6-A7F6-D688F5EE2D62 wds:Q64111023-E85EEF4A-58DF-482C-9BAC-95EEB57ED746
cites work	How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease? GRADE: an emerging consensus on rating quality of evidence and strength of recommendations Inhaled corticosteroid adherence and emergency department utilization among Medicaid-enrolled children with asthma Risk factors for asthma-related healthcare use: longitudinal analysis using the NHI claims database in a Korean asthma cohort A questionnaire to assess the relevance and credibility of observational studies to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers Impact of asthma controller medications on clinical, economic, and patient-reported outcomes Asthma control with extrafine-particle hydrofluoroalkane-beclometasone vs. large-particle chlorofluorocarbon-beclometasone: a real-world observational study De testimonio: on the evidence for decisions about the use of therapeutic interventions Integrating real-life studies in the global therapeutic research framework. The GRACE checklist for rating the quality of observational studies of comparative effectiveness: a tale of hope and caution Quality standards for real-world research. Focus on observational database studies of comparative effectiveness Dispensation of long-acting β agonists with or without inhaled corticosteroids, and risk of asthma-related hospitalisation: a population-based study. 1-year prospective real life monitoring of asthma control and quality of life in Italy Real-life effectiveness of extrafine beclometasone dipropionate/formoterol in adults with persistent asthma according to smoking status Adequate levels of adherence with controller medication is associated with increased use of rescue medication in asthmatic children Real-world research and its importance in respiratory medicine Effectiveness of inhaler types for real-world asthma management: retrospective observational study using the GPRD. Predictors of adherence to treatment in patients with severe asthma treated at a referral center in Bahia, Brazil Switching patients from other inhaled corticosteroid devices to the Easyhaler(®): historical, matched-cohort study of real-life asthma patients Feasibility and ethics A retrospective database analysis on persistence with inhaled corticosteroid therapy: comparison of two dry powder inhalers during asthma treatment in Germany.
author name string	wds:Q64111023-039A0EE1-C02E-48D2-88B7-AC565901AE2F wds:Q64111023-067F51C2-5124-44AB-A3EA-208855C6DAB7 wds:Q64111023-1E3B9C18-20E7-4055-8BB2-CAA29D9F27BC wds:Q64111023-3C3BD2D3-3E55-4967-AF3E-92AF9FC62003 wds:Q64111023-4763F851-C613-448A-93B3-C264AE5EC814 wds:Q64111023-803EE390-29A3-4A7E-BC10-C4C45C89DF93 wds:Q64111023-9E32743D-73E7-4595-B649-F2765B6DD429 wds:Q64111023-E3EC4150-D6CE-48FA-83B6-F4B7AE4677F7 wds:Q64111023-E94A1DA1-62A3-4275-B701-E2AD162DE76E
author name string	Michael Thomas David Price Nikolaos G Papadopoulos Nicolas Roche Eric van Ganse Robert Perry Alison Chisholm Jennifer Quint Jerry Krishnan
rdfs:label	The REal Life EVidence AssessmeNt Tool (nl) The REal Life EVidence AssessmeNt Tool (RELEVANT): development of a novel quality assurance asset to rate observational comparative effectiveness research studies (en)
skos:prefLabel	The REal Life EVidence AssessmeNt Tool (nl) The REal Life EVidence AssessmeNt Tool (RELEVANT): development of a novel quality assurance asset to rate observational comparative effectiveness research studies (en)
name	The REal Life EVidence AssessmeNt Tool (nl) The REal Life EVidence AssessmeNt Tool (RELEVANT): development of a novel quality assurance asset to rate observational comparative effectiveness research studies (en)
author	wds:Q64111023-3E1CEF20-BE7A-4C84-B7E6-2E36869811BD wds:Q64111023-57B8661B-5B4F-481C-97CC-D50F19C6BE06 wds:Q64111023-C0A581FE-D16A-40A1-9109-6EB03710746E wds:Q64111023-FE8EB793-BC46-43BE-8869-CD12F10526F2
author	Leif Bjermer Maarten van den Berge Guy Brusselle Jonathan D Campbell
title	wds:Q64111023-53509D3D-A6D2-49F7-965B-183843B32954
title	The REal Life EVidence AssessmeNt Tool (RELEVANT): development of a novel quality assurance asset to rate observational comparative effectiveness research studies (en)
page(s)	wds:Q64111023-67CC264D-A28A-41F5-909C-799E6971C9EE
page(s)	21
instance of	wds:Q64111023-C7E68DC2-A982-4E50-91B7-EE897073960B
instance of	scholarly article
PubMed ID	wds:Q64111023-BA80757E-7373-4F41-B113-90F4A71B9746
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/30962876
PubMed ID	30962876
published in	wds:Q64111023-F4DE62F4-1608-4B08-AA66-DE0D3F8866C3
published in	Clinical and translational allergy
issue	wds:Q64111023-96B4832E-B00E-485D-9904-939D92CD0E25

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software